COMPANY PROFILE

ExoStemTech

Pioneering exosome-based therapeutics for osteoarthritis, liver fibrosis, and lung fibrosis with cutting-edge mass production technology

South KoreaFounded 2016

Valuation $50–100M Last recorded · 2021

Total funding $10–50M Disclosed equity funding

Unlock exact values

About ExoStemTech

ExoStemTech is a biotechnology company specializing in the development of exosome-based therapeutics. The company focuses on creating treatments for various medical conditions, including osteoarthritis, liver fibrosis, and lung fibrosis. ExoStemTech operates in the biopharmaceutical market and serves clients such as healthcare providers, research institutions, and pharmaceutical companies. The company's business model revolves around the mass production and quality control of exosomes, which are small vesicles released by cells that can be used for therapeutic purposes. ExoStemTech generates revenue through the development and commercialization of its proprietary exosome therapies, as well as through partnerships and collaborations with other organizations in the healthcare sector. The company is currently advancing its lead asset for osteoarthritis treatment into phase 1 clinical trials and is developing a pipeline of over eight different therapeutics.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: South Korea
Open positions: None listed
Dealroom signal: 17.7/100
Business model: Manufacturing
Client focus: b2b
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BEquity / VC	Oct 2021	$8.4M	$34M	Hana Financial Investment · WeVenture · DSC Investment · Laguna Investment	↗
SERIES B✓Equity / VC	Jan 2021	$15M	$62M	Undisclosed	—